奈妥匹坦帕洛诺司琼胶囊:一种新型的预防化疗所致恶心呕吐的固定剂量复方制剂

Netupitant and palonosetron hydrochloride capsules,a new fixed-dose combination drug for the prevention of chemotherapy-induced nausea and vomiting

化疗所致恶心呕吐(CINV)是肿瘤患者化疗过程中最常见的不良反应之一。目前,CINV控制不满意的现象仍普遍存在。奈妥匹坦帕洛诺司琼胶囊(NEPA)是一种由高亲和力的新型神经激肽1受体拮抗剂奈妥匹坦和第二代5-羟色胺3受体拮抗剂帕洛诺司琼组成的固定剂量复方制剂。NEPA作为全球第一个止吐药物的固定剂量复方制剂,同时靶向阻断CINV的两条关键通路,潜在地改善临床指南依从性和用药依从性,有利于提高CINV管理质量,为患者带来获益。

Chemotherapy-induced nausea and vomiting(CINV)is one of the most common adverse reaction in chemotherapy.Currently,CINV is still a challenge without well-controlled generally.Netupitant and palonosetron hydrochloride capsules(NEPA)is a fixed-dose combination of netupitant,a novel,highly selective neurokinin 1 receptor antagonist,and palonosetron,a new-generation 5-hydroxytryptamine 3 receptor antagonist.NEPA is the first fixed-dose combination of antiemetic drug in the world,targeting two major emetic pathways involved in CINV.NEPA has the potential to improve adherence of guidelines and medication,and benefits patients by improving the quality of CINV management.